Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides the highest quality and innovative anti-CYP11A1 antibodies globally, to accelerate the biological understanding of the target CYP11A1. Our antibodies are meticulously developed to ensure exceptional specificity and reliability, making them invaluable tools for researchers. By supporting studies related to CYP11A1, we aim to enhance the exploration of its role in various biological processes. With our commitment to excellence, we empower scientists to achieve groundbreaking discoveries in their respective fields.
The target CYP11A1 (cytochrome P450 family 11 subfamily A member 1) is an important enzyme involved in steroid hormone biosynthesis. CYP11A1 catalyzes the conversion of cholesterol to pregnenolone, which is the first and rate-limiting step in the synthesis of all steroid hormones. Research on CYP11A1 is significant as it provides insights into the regulation of steroid hormone production and its role in various physiological and pathological processes. Understanding CYP11A1 may lead to the development of novel therapeutic strategies for diseases related to steroid hormone imbalance, such as endocrine disorders and certain cancers. Additionally, CYP11A1 may serve as a potential target for drug development to modulate steroid hormone levels and treat related diseases.
Cytochrome P450 family 11 subfamily A member 1; CYP11A; CYPXIA1; P450SCC
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins
Intracellular
Cell type enhanced (Syncytiotrophoblasts, Theca cells, Extravillous trophoblasts, Peritubular cells)
Immune cell enriched (basophil)
Group enriched (BEWO, HEL)
Interacts with FDX1/adrenodoxin.
Monooxygenase, Oxidoreductase
We take great pride in offering top-notch anti-CYP11A1 recombinant antibody products. These are crafted to enhance and expedite biological research focused on the CYP11A1 target. With our quality offerings, we strive to play a significant role in advancing understanding within this scientific domain.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-2019z | Mouse Anti-CYP11A1 Recombinant Antibody | Human; Mouse; Rat | Mouse | WB; IHC; ELISA |
MOB-2019z-S(P) | Recombinant Anti-Human CYP11A1 Antibody scFv Fragment | Human | Mouse | FC; Neut; Funcs |
MOB-2019z-F(E) | Recombinant Anti-Human CYP11A1 Antibody Fab Fragment | Human | Mouse | IP; FuncS |
We boast years of extensive experience in the production and optimization of recombinant antibodies. Committed to delivering the highest quality service, we strive to provide you with top-notch recombinant antibody products. In the shortest possible time, we ensure quality and excellence for your needs.
Featured Anti-CYP11A1 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
At Creative Biolabs, we provide multiple antibody formats of high quality. This is because we aim to meet the diverse requirements of our customers. We recognize that various research projects and applications call for different antibody formats, so we are dedicated to offering a broad selection.
Fig.3 Full Length Anti-CYP11A1 Recombinant Antibody Production and Modalities.
Table 1. Therapeutic approaches targeting CYP11A1 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase III |
Merck & Co Orion (FI) (Originator) |
Small Molecules | Cancer | This is an oral CYP11A1 inhibitor in phase III development at Orion and Merck & Co for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), with or without hormone replacement therapy (HRT). |
Phase I/II | Orion (FI) | Others | Cancer | It is a CYP11A1 inhibitor in phase I/II clinical development at Orion (FI) for the oral treatment of patients with metastatic castration-resistant prostate cancer or with ER-positive, HER2-negative breast cancer. |
For additional details regarding anti-CYP11A1 recombinant antibody products, please feel free to contact us at any time. Our team is here to assist you with any inquiries. We look forward to establishing a collaborative partnership that supports your research goals and contributes to your scientific success.